Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

FDA assigns action date for Orexo's Zubsolv NDA

Nov. 19, 2012

No Comments

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

Nov. 9, 2012

No Comments

ADX-71441 shows promise in preclinical model of alcohol binge drinking

Oct. 30, 2012

No Comments

DepoVax found to enhance effect of investigational cocaine vaccine

Oct. 26, 2012

No Comments

Nabi Biopharmaceuticals reports results from phase II NicVAX vaccine study

Oct. 18, 2012

No Comments

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

Sep. 28, 2012

No Comments

University of Pittsburg presents new radioprotectants

Sep. 17, 2012

No Comments

Pivotal pharmacokinetic study of BEMA-buprenorphine/naloxone meets objectives

Sep. 14, 2012

No Comments

Orexo submits NDA for sublingual buprenorphine/naloxone product

Sep. 7, 2012

No Comments

New funding supports Cellerant's development of CLT-008

Sep. 5, 2012

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Substance use and poisoning
RSS

FDA assigns action date for Orexo's Zubsolv NDA

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

ADX-71441 shows promise in preclinical model of alcohol binge drinking

DepoVax found to enhance effect of investigational cocaine vaccine

Nabi Biopharmaceuticals reports results from phase II NicVAX vaccine study

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

University of Pittsburg presents new radioprotectants

Pivotal pharmacokinetic study of BEMA-buprenorphine/naloxone meets objectives

Orexo submits NDA for sublingual buprenorphine/naloxone product

New funding supports Cellerant's development of CLT-008

Today's news in brief

Today's news in brief

In muscular dystrophies, gene therapies race the clock

Bridgebio, with FDA approval, faces Pfizer in ATTR

Radiopharma Telix acquires FAP-targeting agents for bladder cancer

Substance use and poisoning RSS

Substance use and poisoning
RSS